FeRx Report issue

For profit Phase 3
Founded: San Diego CA United States (1997)
Status: Defunct (2008)

Organization Overview

First Clinical Trial
2001
NCT00054951
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

doxorubicin (Doxil) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Digestive System Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1